Will Vaccines Really Work for Melanoma?

Hersey, Peter

doi:10.1002/9780470987346.ch16

Cited by 2 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Now, with improvements in our understanding of immune responses to tumors, rapid advances in molecular biologic approaches and the identification of potential tumor antigens, vaccines have been developed that are being evaluated in a number of clinical trials [54]. In fact, several large co-operative groups have recently reported the results of early vaccine trials.…”

Section: Five-year Viewmentioning

confidence: 99%

Interferon-α in high-risk melanoma patients

Cormier

Xing

Ross

et al. 2004

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

The incidence of melanoma has been climbing steadily since the early 1970s. Although melanoma can be successfully cured by surgical excision in its early stages, it is the most common fatal form of skin cancer. The most critical factors in determining the prognosis for patients with melanoma are primary tumor thickness, ulceration and the status of regional lymph nodes. Surgical treatment alone is inadequate in patients with thick, ulcerated tumors and those with nodal disease, as shown by poor 5-year disease-specific survival rates. Despite the fact that high-dose interferon-alpha has been approved for the treatment of high-risk melanoma by the US Food and Drug Administration and regulatory agencies worldwide, current treatment recommendations vary widely due to the conflicting trial data and significant toxicity and cost associated with high-dose interferon-alpha.

show abstract

Section: Five-year Viewmentioning

confidence: 99%

Interferon-α in high-risk melanoma patients

Cormier

Xing

Ross

et al. 2004

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

“…A large number of melanoma antigens recognized by T cells has now been classified as: (i) differentiation antigens, (ii) tumour‐specific cancer‐testis antigens (TSA), (iii) overexpressed antigens and (iv) indiv‐idual specific antigens. Peptide epitopes from these antigens are the subject of a large number of phase I/II trials 58−60 . Very few studies have yet been initiated to test adjuvant immunotherapy with purified peptides.…”

Section: New Directions In Vaccine Treatment Of Melanomamentioning

confidence: 99%

Adjuvant therapy for high‐risk primary and resected metastatic melanoma

Hersey

2003

Internal Medicine Journal

View full text Add to dashboard Cite

Patients with thick, primary melanoma and regional lymph-node metastases are at moderate to high risk of recurrence and death, despite apparent complete surgical removal. Immune responses can be demonstrated against melanoma and this has prompted the conduct of a number of randomized trials of immunotherapy. Several trials have been completed and show minimal benefit in prolonging survival or recurrence from melanoma. Similarly, a large number of trials has been conducted to test the efficacy of alpha-2-interferon (IFN-alpha2) in therapy. Clear benefit in recurrence-free survival was shown in several trials, however there is a lack of convincing evidence of an effect on overall survival. Several trials of vaccine and IFN-alpha2 therapy are still in progress and their results are awaited with great interest. The use of high-dose IFN-alpha2 therapy remains a contentious subject, however available evidence suggests the standard of care remains good surgical management.

show abstract

Will Vaccines Really Work for Melanoma?

Cited by 2 publications

References 67 publications

Interferon-α in high-risk melanoma patients

Interferon-α in high-risk melanoma patients

Adjuvant therapy for high‐risk primary and resected metastatic melanoma

Contact Info

Product

Resources

About